{"id":"https://openalex.org/W4361887641","doi":"https://doi.org/10.1158/1078-0432.22471542","title":"Supplementary Figures from Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab","display_name":"Supplementary Figures from Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361887641","doi":"https://doi.org/10.1158/1078-0432.22471542"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22471542","doi":"https://doi.org/10.1158/1078-0432.22471542","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22471542","pdf_url":"https://aacr.figshare.com/ndownloader/files/39923025","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/ndownloader/files/39923025","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028592995","display_name":"Omid Hamid","orcid":"https://orcid.org/0000-0002-8238-4655","observed_orcids":["https://orcid.org/0000-0002-8238-4655"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Omid Hamid","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056037326","display_name":"Luciana Lorena Molinero","orcid":"https://orcid.org/0000-0001-5866-5214","observed_orcids":["https://orcid.org/0000-0001-5866-5214"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Luciana Molinero","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089159928","display_name":"Christopher R. Bolen","orcid":"https://orcid.org/0000-0003-2270-5565","observed_orcids":["https://orcid.org/0000-0003-2270-5565"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher R. Bolen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075566772","display_name":"Jeffrey Alan Sosman","orcid":"https://orcid.org/0000-0002-0650-9698","observed_orcids":["https://orcid.org/0000-0002-0650-9698"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey A. Sosman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058294413","display_name":"Eva Mu\u00f1oz\u2010Couselo","orcid":"https://orcid.org/0000-0001-7556-7608","observed_orcids":["https://orcid.org/0000-0001-7556-7608"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eva Mu\u00f1oz-Couselo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001175430","display_name":"Harriet M. Kluger","orcid":"https://orcid.org/0000-0002-4932-9873","observed_orcids":["https://orcid.org/0000-0002-4932-9873"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Harriet M. Kluger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007052233","display_name":"David F. McDermott","orcid":"https://orcid.org/0000-0002-2675-5095","observed_orcids":["https://orcid.org/0000-0002-2675-5095","https://orcid.org/0000-0001-6978-0867"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David F. McDermott","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020534158","display_name":"John D. Powderly","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John D. Powderly","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Indrani Sarkar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Indrani Sarkar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112302361","display_name":"Marcus D. Ballinger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marcus Ballinger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005597325","display_name":"Marcella Fass\u00f2","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marcella Fass\u00f2","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086994520","display_name":"Carol Elaine O'Hear","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carol O'Hear","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038215538","display_name":"Daniel S. Chen","orcid":"https://orcid.org/0000-0001-5085-3579","observed_orcids":["https://orcid.org/0000-0001-5085-3579"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel S. Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110860414","display_name":"Priti S. Hegde","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Priti S. Hegde","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5084967339","display_name":"Frank Stephen Hodi","orcid":"https://orcid.org/0000-0001-6825-091X","observed_orcids":["https://orcid.org/0000-0001-6825-091X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Stephen Hodi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0052999998442828655,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9490000009536743},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7770000100135803},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.718999981880188},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7179999947547913},{"id":"https://openalex.org/keywords/clinical-activity","display_name":"clinical activity","score":0.9309999942779541}],"concepts":[{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.9679995179176331},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5284457206726074},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5155332088470459},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.513587236404419},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.47148868441581726},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.4581659436225891},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4526002109050751},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.27395740151405334},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.15479114651679993},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.12069272994995117},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.11635467410087585}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22471542","doi":"https://doi.org/10.1158/1078-0432.22471542","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22471542","pdf_url":"https://aacr.figshare.com/ndownloader/files/39923025","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22471542.v1","doi":"https://doi.org/10.1158/1078-0432.22471542.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22471542.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22471542","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figures_from_Safety_Clinical_Activity_and_Biological_Correlates_of_Response_in_Patients_with_Metastatic_Melanoma_Results_from_a_Phase_I_Trial_of_Atezolizumab/22471542","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22471542","doi":"https://doi.org/10.1158/1078-0432.22471542","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22471542","pdf_url":"https://aacr.figshare.com/ndownloader/files/39923025","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361887641.pdf","grobid_xml":"https://content.openalex.org/works/W4361887641.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4240975925","https://openalex.org/W3024739100","https://openalex.org/W2966816506","https://openalex.org/W4361946908","https://openalex.org/W7100403823","https://openalex.org/W4402806537","https://openalex.org/W4402821451"],"abstract_inverted_index":{"Figures":[0],"S1-S4":[1]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}